164 related articles for article (PubMed ID: 11123866)
1. Genetic factors in ovarian carcinoma.
Li AJ; Karlan BY
Curr Oncol Rep; 2001 Jan; 3(1):27-32. PubMed ID: 11123866
[TBL] [Abstract][Full Text] [Related]
2. Genetics and ovarian carcinoma.
Lynch HT; Casey MJ; Lynch J; White TE; Godwin AK
Semin Oncol; 1998 Jun; 25(3):265-80. PubMed ID: 9633840
[TBL] [Abstract][Full Text] [Related]
3. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).
Aunoble B; Sanches R; Didier E; Bignon YJ
Int J Oncol; 2000 Mar; 16(3):567-76. PubMed ID: 10675491
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of ovarian carcinomas.
Matias-Guiu X; Prat J
Virchows Arch; 1998 Aug; 433(2):103-11. PubMed ID: 9737787
[TBL] [Abstract][Full Text] [Related]
6. [Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer].
Zikán M; Pohlreich P; Freitag P; Janousek M; Pavlista D; Fischerová D; Jancárková N; Sláma J; Pinkavová I; Cibula D
Ceska Gynekol; 2008 Oct; 73(5):298-302. PubMed ID: 19110958
[TBL] [Abstract][Full Text] [Related]
7. Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?
Kim KY; Park DW; Jeung EB; Choi KC
J Vet Sci; 2010 Dec; 11(4):291-7. PubMed ID: 21113097
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of ovarian cancer.
Gallion HH; Pieretti M; DePriest PD; van Nagell JR
Cancer; 1995 Nov; 76(10 Suppl):1992-7. PubMed ID: 8634990
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
10. Advances in the molecular genetics of endometrial cancer (Review).
Esteller M; Xercavins J; Reventos J
Oncol Rep; 1999; 6(6):1377-82. PubMed ID: 10523715
[TBL] [Abstract][Full Text] [Related]
11. [Recent developments in the molecular genetic understanding of ovarian carcinoma].
Shimizu Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():489-95. PubMed ID: 15535294
[No Abstract] [Full Text] [Related]
12. p53 and HER-2/neu overexpression in ovarian borderline tumors.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
14. Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers.
Rajkumar T; Meenakumari B; Mani S; Sridevi V; Sundersingh S
Asian Pac J Cancer Prev; 2015; 16(13):5211-7. PubMed ID: 26225655
[TBL] [Abstract][Full Text] [Related]
15. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
16. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
19. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
20. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
